NCT07406347

A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age

A Phase 1, Observer-blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 42 Days – 90 Days
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study

Conditions

• Pneumonia, Bacterial

Interventions

Type	Name	Description
BIOLOGICAL	Pn-MAPS30plus	Pn-MAPS30plus vaccine will be administered intramuscularly.
COMBINATION_PRODUCT	PCV20	PCV20 vaccine will be administered intramuscularly.

Timeline

• Start date: 2026-07-10
• Primary completion: 2028-04-03
• Completion: 2028-04-03
• First posted: 2026-02-12
• Last updated: 2026-02-12